Clinical Trial Update: Bosentan In Exercise Induced Pulmonary Arterial Hypertension in CongenitaL Heart diseasE [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing bosentan for exercise-induced pulmonary arterial hypertension in patients with congenital heart disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Heart Disease
• Pulmonary Arterial Hypertension

Drugs mentioned

• Bosentan (Bosentan)

Snippet

Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Conditions: Pulmonary Arterial Hypertension, Congenital Heart Disease | Phase 2 | Status: UNKNOWN